Creutzfeldt-Jakob disease overview

Jump to navigation Jump to search

Creutzfeldt-Jakob disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Creutzfeldt-Jakob disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Creutzfeldt-Jakob disease overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Creutzfeldt-Jakob disease overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Creutzfeldt-Jakob disease overview

CDC on Creutzfeldt-Jakob disease overview

Creutzfeldt-Jakob disease overview in the news

Blogs on Creutzfeldt-Jakob disease overview

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Creutzfeldt-Jakob disease overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.

Overview

Creutzfeldt-Jakob disease is a very rare, invariably fatal degenerative neurological disorder of the brain. It is caused by the presence of a prion protein, an abnormal isoform of a cellular glycoprotein.[1] Creutzfeldt-Jakob disease may be classified into either sporadic, familial and iatrogenic forms. The sporadic form may be further categorized into either classic or variant Creutzfeldt-Jakob disease. The majority of cases of Creutzfeldt-Jakob disease are thought to occur sporadically from prions by an unknown route of transmission. Reports on transmission by human growth hormone products, grafting, surgical electrode implantation, and consumption of infected products have been described. Once transmitted, the CJD prion promotes refolding of the native proteins into the diseased state. The number of misfolded protein molecules increases exponentially, and the process leads to a large quantity of insoluble prions in the affected cells, resulting in cell death. Risk factors for Creutzfeldt-Jakob disease include advanced age, positive family history, personal history of psychosis, history of surgical procedures, grafts or implants, and history of ingestion of human growth hormones or contaminated meat. Once symptoms develop, Creutzfeldt-Jakob disease is rapidly progressive and almost always fatal. Early symptoms are often non-specific. Patients' relatives usually report rapidly progressive dementia, personality changes, uncontrolled sporadic laughter, and sleep disorders. The majority of patients (85% of patients) die within 1 year of symptom-onset. Common complications of Creutzfeldt-Jakob disease include overwhelming infections, congestive heart failure, or respiratory failure. The diagnosis of Creutzfeldt Jakob disease depends on a combination of positive findings from physical examination and laboratory testing. Based on the findings, the diagnosis of Creutzfeldt Jakob disease may be either probable or possible. There are no definitive criteria for the diagnosis of Creutzfeldt Jakob disease. Typical EEG findings in Creutzfeldt-Jakob disease include periodic biphasic or triphasic sharp wave complexes (PSWCs). Periodic synchronous discharges (PSDs) occur either before or in synchronicity with myoclonus. Biopsy of the brain tissue is the definitive diagnostic test for Creutzfeldt-Jakob disease, but is not usually performed. Management of Creutzfeldt-Jakob disease is directed towards palliative care. There is no effective treatment or vaccine for Creutzfeldt Jakob disease.

Historical Perspective

Creutzfeldt Jakob disease was first described in 1920-1921 by two German neurologists, Hans Gerhard Creutzfeldt and Alfons Maria Jakob.

Classification

Creutzfeldt-Jakob disease may be classified into either sporadic, familial and iatrogenic forms. The sporadic form may be further categorized into either classic or variant Creutzfeldt-Jakob disease.

Pathophysiology

The majority of cases of Creutzfeldt-Jakob disease are thought to occur sporadically from prions by an unknown route of transmission. Reports on transmission by human growth hormone products, grafting, surgical electrode implantation, and consumption of infected products have been described. Once transmitted, the CJD prion promotes refolding of the native proteins into the diseased state. The number of misfolded protein molecules increases exponentially, and the process leads to a large quantity of insoluble prions in the affected cells, resulting in cell death. On gross histopathological analysis, the brain tissue appears "spongy" with areas of perforation within the brain tissue. On microscopic histopathological analysis, spongiform changes, neuronal loss, astrocyte proliferation, and deposition of prion proteins in the brain are characteristic findings.

Causes

Creutzfeldt-Jakob disease (CJD) is caused by the presence of a prion protein, an abnormal isoform of a cellular glycoprotein.[1]

Differential Diagnosis

Creutzfeldt-Jakob disease must be differentiated from other causes of rapidly progressive dementia, such as other neurodegenerative diseases, infections, Alzheimer's disease, vascular dementia, and dementia due to metabolic or toxic etiology.[2]

Epidemiology and Demographics

Creutzfeldt-Jakob disease is a rare disorder with an incidence of approximately 0.1 to 0.3 cases per 100,000 individuals. In the USA, less than 300 cases of Creutzfeldt-Jakob disease have been reported. Individuals > 50 years of age are at higher risk of developing Creutzfeldt-Jakob disease than younger individuals. The most common age at diagnosis is approximately 60-65 years (range 45-90). On the other hand, variant (non-classic) Creutzfeldt-Jakob disease is more common among younger individuals. There is no gender or racial predilection for the development of Creutzfeldt-Jakob disease. Creutzfeldt-Jakob disease is more commonly described in Africa, but this is thought to be attributed to cannibalism practices in certain African tribes in the 1950s and ingestion of infected human brains, rather than true racial variation.

Risk Factors

Risk factors for Creutzfeldt-Jakob disease include advanced age, positive family history, personal history of psychosis, history of surgical procedures, grafts or implants, and history of ingestion of human growth hormones or contaminated meat.

Natural History, Complications and Prognosis

Once symptoms develop, Creutzfeldt-Jakob disease is rapidly progressive and almost always fatal. Early symptoms are often non-specific. Patients' relatives usually report rapidly progressive dementia, personality changes, uncontrolled sporadic laughter, and sleep disorders. The majority of patients (85% of patients) die within 1 year of symptom-onset. Common complications of Creutzfeldt-Jakob disease include overwhelming infections, congestive heart failure, or respiratory failure.

Diagnosis

Diagnostic Criteria

The diagnosis of Creutzfeldt Jakob disease depends on a combination of positive findings from physical examination and laboratory testing. Based on the findings, the diagnosis of Creutzfeldt Jakob disease may be either probable or possible. There are no definitive criteria for the diagnosis of Creutzfeldt Jakob disease.

History and Symptoms

Common symptoms of Creutzfeldt-Jakob disease include progressive dementia, depression, personality changes, uncontrolled sporadic laughter, sleep disorders, and jerky movements (characteristic myoclonus).[3]

Physical Examination

Physical examination is required for the diagnosis of ‪Creutzfeldt-Jakob disease‬. Physical examination findings of ‪Creutzfeldt-Jakob disease‬findings include myoclonus, extrapyramidal signs, akinetic mutism, and visual or cerebellar signs[4]

Laboratory Findings

Routine laboratory tests are usually normal in Creutzfeldt Jakob disease. Analysis of CSF for 14-3-3 protein may be helpful in the diagnosis of Creutzfeldt-Jakob disease‬.[5] Other elevated proteins in CSF may include S-100, neuron specific enolase, and Tau protein.

MRI

MRI findings in CJD include high signal abnormalities in caudate nucleus and/or putamen on diffusion-weighted imaging (DWI) or fluid attenuated inversion recovery (FLAIR).[1] Additional findings on diffusion weighted imaging include cortical, subcortical, and thalamic involvement. An abnormal signal in the poster thalami on T2 (pulvinar sign) and diffusion weighted images and fluid-attenuated inversion recovery sequences on brain MRI, in the appropriate clinical context, is highly specific for variant Creutzfeldt-Jakob disease.

CT and PET Scan

CT and PET scans are generally normal in Creutzfeldt-Jakob disease and may be helpful in ruling out other diseases. On CT scan, rapidly progressive ventricular enlargement and cortical atrophy may be present. On PET scan, abnormalities in thalamic regions may be present.

EEG

EEG findings are not diagnostic of CJD, but may help in the diagnosis of CJD. Typical EEG findings in Creutzfeldt-Jakob disease include periodic biphasic or triphasic sharp wave complexes (PSWCs). Periodic synchronous discharges (PSDs) occur either before or in synchronicity with myoclonus.[6]

Biopsy

Biopsy of the brain tissue is the definitive diagnostic test for Creutzfeldt-Jakob disease, but is not usually performed. Deposits of prion protein (scrapie), PrPSc, can be found in the skeletal muscle and/or the spleen (approximately 30% of cases).

Treatment

Medical Therapy

Management of Creutzfeldt-Jakob disease is directed towards palliative care. There is no effective treatment for Creutzfeldt Jakob disease.

Primary Prevention

There is no vaccine against Creutzfeldt-Jakob disease. Preventive measures to reduce Creutzfeldt-Jakob disease have not been studied and may or may not be helpful. Preventive measures may include sterilizing medical equipment before use, avoiding the use of infected patients as cornea donors, managing infected animals (e.g. cows), and not accepting transfusions from individuals with certain travel histories (e.g. travel to UK for > 6 months between 1980-1996).

References

  1. 1.0 1.1 1.2 "http://www.cdc.gov/ncidod/dvrd/cjd/qa_cjd_infection_control.htm#what". Retrieved 14 February 2014. External link in |title= (help)
  2. Paterson RW, Torres-Chae CC, Kuo AL, Ando T, Nguyen EA, Wong K; et al. (2012). "Differential diagnosis of jakob-creutzfeldt disease". Arch Neurol. 69 (12): 1578–82. doi:10.1001/2013.jamaneurol.79. PMID 23229042.
  3. Haywood, AM. (1997). "Transmissible spongiform encephalopathies". N Engl J Med. 337 (25): 1821–8. doi:10.1056/NEJM199712183372508. PMID 9400041. Unknown parameter |month= ignored (help)
  4. Rabinovici, GD.; Wang, PN.; Levin, J.; Cook, L.; Pravdin, M.; Davis, J.; DeArmond, SJ.; Barbaro, NM.; Martindale, J. (2006). "First symptom in sporadic Creutzfeldt-Jakob disease". Neurology. 66 (2): 286–7. doi:10.1212/01.wnl.0000196440.00297.67. PMID 16434680. Unknown parameter |month= ignored (help)
  5. Muayqil, T.; Gronseth, G.; Camicioli, R. (2012). "Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology". Neurology. 79 (14): 1499–506. doi:10.1212/WNL.0b013e31826d5fc3. PMID 22993290. Unknown parameter |month= ignored (help)
  6. Hayashi, R.; Hanyu, N.; Kuwabara, T.; Moriyama, S. (1992). "Serial computed tomographic and electroencephalographic studies in Creutzfeldt-Jakob disease". Acta Neurol Scand. 85 (3): 161–5. PMID 1574996. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources